Shopping Cart
Remove All
Your shopping cart is currently empty
YF-2 is blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, CBP, PCAF, and GCN5 with EC50s of 2.75 μM, 29.04 μM and 49.31 μM , respectively

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $50 | In Stock | In Stock | |
| 5 mg | $122 | In Stock | In Stock | |
| 10 mg | $197 | In Stock | In Stock | |
| 25 mg | $413 | In Stock | In Stock | |
| 50 mg | $618 | In Stock | In Stock | |
| 100 mg | $879 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $133 | In Stock | In Stock |
| Description | YF-2 is blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, CBP, PCAF, and GCN5 with EC50s of 2.75 μM, 29.04 μM and 49.31 μM , respectively |
| Targets&IC50 | GCN5:49.31 μM, PCAF:29.04 μM , CBP:2.75 μM |
| In vitro | YF-2 (0.03, 0.1, 0.25, 0.5, 1, 2.5, 5, 15, 40 and 80 μM, 72 hours) inhibits the preliferation of U251, CCRF-CEM, Hs578T, NCI-ADR-RES cells, respectively. |
| In vivo | YF-2, administered intraperitoneally at doses of 20 mg/kg (2 hours before an electric shock) or 5 mg/kg (30 minutes prior to the electric shock), effectively rescues the defect in contextual memory in mice. At a dosage of 20 mg/kg without the electric shock treatment, YF-2 exhibits no impact on contextual memory in mice. |
| Molecular Weight | 430.85 |
| Formula | C20H22ClF3N2O3 |
| Cas No. | 1311423-89-8 |
| Smiles | CCOc1cccc(OCCN(C)C)c1C(=O)Nc1ccc(Cl)c(c1)C(F)(F)F |
| Relative Density. | 1.285 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: Insoluble DMSO: 125 mg/mL (290.12 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.